PUBLISHER: IMARC | PRODUCT CODE: 1831863
PUBLISHER: IMARC | PRODUCT CODE: 1831863
The global platelet aggregation devices market size reached USD 585.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 917.7 Million by 2033, exhibiting a growth rate (CAGR) of 4.87% during 2025-2033.
Platelet aggregation devices comprise adenosine-diphosphate (ADP), thrombin, and ristocetin-induced platelet aggregation (RIPA). These devices are used to diagnose patients with inherited and acquired platelet function disorders, such as excessive bleeding, arterial thrombotic, stroke, and myocardial infarction. They assist in transfusing medicines, pre-surgery tests, and clinical settings to monitor the response of antiplatelet therapies and assess perioperative bleeding risk. At present, due to the launch of new potential biomarkers and technologies, platelet aggregation devices are finding extensive application in personalizing antiplatelet drugs and monitoring the efficacy of various types of pro-hemostatic therapies around the world.
The rising instances of platelet aggregation among patients diagnosed with coronavirus disease (COVID-19) are strengthening the growth of the market. Moreover, due to the growing prevalence of colon cancer, cardiovascular diseases, Kawasaki condition, acute coronary syndrome (ACS), acute ischemic stroke, and acute rheumatic disorders across the globe, there is an increase in the risk of bleeding. This acts as another key factor impelling the growth of the platelet aggregation devices market for clinical management of platelet function disorders. In addition, a significant rise in the aging population suffering from chronic diseases is contributing to the market growth. Apart from this, leading manufacturers are launching novel products to expand their product portfolio and retain a competitive edge in the market. They are also focusing on developing new and simpler point-of-care (POC) diagnostic devices. These devices rely on the latest methodologies for helping in the rapid evaluation of inherited and acquired bleeding disorders and antiplatelet therapies. This, coupled with the increasing need for POC diagnostic devices to fulfill the healthcare demand of the large population, is projected to drive the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aggredyne Inc., Chrono-Log Corporation, F. Hoffmann-La Roche AG, Grifols S.A., Hart Biologicals Ltd., Helena Laboratories Corporation, LAbor BioMedical Technologies GmbH, Matis Medical Inc., Sentinel Ch. S.P.A., Siemens AG, Sienco Inc., Sysmex Corporation and WerfenLife SA.